SEGG Media Corp. (NASDAQ: SEGG)

The QualityStocks Daily Newsletter would like to spotlight SEGG Media Corp. (NASDAQ: SEGG).

SEGG Media (NASDAQ: SEGG, LTRYW) , a global sports, entertainment and gaming conglomerate, announced the launch of Sports.com Studios in Mexico as a regional hub for sports and entertainment content in LATAM. Sports.com Studios will produce scalable, locally relevant programming and debut its first project, the Spanish-language reality series Maximo Futbol , on Sept. 30 exclusively through Sports.com. Featuring top Mexican athletes, including the UVM Lynxes collegiate team, the series is supported by sponsors Samsung, Wilson and JAC. Leadership said the new studio will strengthen SEGG Media's ecosystem by combining trusted lottery platforms with original sports content to drive engagement, revenue growth and international expansion.

To view the full press release, visit https://ibn.fm/r9wcd

SEGG Media Corp. (NASDAQ: SEGG; LTRYW) is a global sports, entertainment, and gaming company redefining how audiences connect with content through immersive technology and ethical engagement. Formerly known as Lottery.com Inc., the company recently completed a comprehensive corporate transformation, rebranding as SEGG Media (short for Sports Entertainment Gaming Global Media) to reflect its new strategic direction and structural overhaul.

With a mission to fuse real-time experiences, fan-first platforms, and responsible innovation, SEGG Media operates at the intersection of sports, entertainment, and gaming. Its business model is built around three synergistic verticals, each designed to scale globally while delivering meaningful value to fans, partners, and shareholders.

From sim racing and esports to live event streaming and charitable gaming, SEGG Media is building a next-generation platform that redefines how audiences interact with their favorite content and communities.

The company is headquartered in Fort Worth, Texas.

Portfolio

SEGG Media’s operations are structured across three core verticals: Sports.com, Entertainment, and Lottery.com.

• Sports.com is SEGG’s global hub for immersive sports media, covering sim racing, football, motorsports, and athlete-led content. The vertical includes Sports.com Studios, Sports.com Media, and Nook, each focused on original storytelling and fan-driven experiences. In June 2025, SEGG announced plans to acquire a 51% stake in the sports and technology assets of GXR World to launch the Sports.com Super App, a first-of-its-kind platform combining live streaming, e-commerce, community chat, real-money and fantasy gaming, and sports news. Built on GXR’s tech stack, which already draws over one million monthly active users, the Super App is expected to debut in Q3 2025 with an initial focus on soccer and motorsports.
• The Entertainment pillar includes AI-driven event streaming, music and fashion media, and hybrid live experiences. As part of its acquisition-led growth model, SEGG is advancing a proposed deal to acquire DotCom Ventures Inc., owner of Concerts.com and TicketStub.com, to build out ticketing, event distribution, and direct-to-fan monetization infrastructure. This initiative aligns with SEGG’s five-year plan to unify content, commerce, and fan engagement under one platform, supported by a $100 million financing facility activated in May 2025.
• Lottery.com, SEGG’s ethical gaming division, delivers domestic and international lottery access, iGaming, instant wins, sports betting, charitable gaming through properties such as WinTogether, and syndicated results data to more than 800 publishers through Tinbu. With compliance issues resolved and new operating structures in place, the platform is being relaunched globally through Lottery.com International.

Together, these three verticals enable SEGG Media to unify fragmented fan experiences into a fully integrated global ecosystem—where sports, gaming, content, and commerce converge.

Market Opportunity

The global sports betting industry is undergoing rapid expansion as digital adoption accelerates and new markets open to regulation. According to Grand View Research, the sports betting market was valued at $100.9 billion in 2024 and is projected to reach $187.39 billion by 2030, growing at a compound annual growth rate of 11% from 2025 to 2030. This growth is fueled by increased internet penetration, widespread mobile usage, and rising interest in real-time, interactive fan experiences.

Beyond sports betting, SEGG Media also operates in the high-growth arenas of streaming, esports, and AI-powered content delivery. These adjacent markets are seeing double-digit global growth as fans demand more immersive, on-demand, and participatory forms of entertainment. With its diversified platform and strategic positioning across three converging verticals, SEGG Media is built to capitalize on multiple long-term secular trends and unlock scalable revenue opportunities.

Leadership Team

Matthew McGahan, Chief Executive Officer and Chairman, joined the company in October 2022. Since then, he has played a central role in stabilizing operations, restructuring the organization, and guiding its rebrand to SEGG Media. McGahan brings a mix of entrepreneurial drive and philanthropic leadership, having founded the UK-based charity Mask Our Heroes during the COVID-19 pandemic and previously built and sold the Harley-Davidson dealership Magic Automotive Group.

Tim Scoffham, CEO of Sports.com Media and Lottery.com International, brings over 20 years of leadership experience across gaming, media, and digital sports entertainment. Appointed following a successful consultancy period, Scoffham now leads SEGG’s global growth strategy for its iGaming and sports media divisions. He is focused on expanding international operations, aligning media and technology platforms, and driving revenue across high-growth jurisdictions while strengthening regulatory partnerships.

SEGG Media Corp. (NASDAQ: SEGG), closed Friday's trading session at $5.4, up 4.0462%, on 125,861 volume. The average volume for the last 3 months is 117,032 and the stock's 52-week low/high is $2.202/$26.45.

Recent News

• SEGG Media Corp. (NASDAQ: SEGG) - TinyGemsBreaks - SEGG Media Corporation (NASDAQ: SEGG, LTRYW) Launches Sports.com Studios in Mexico With Premiere of Original Series
• NetworkNewsBreaks - SEGG Media Corporation (NASDAQ: SEGG, LTRYW) Secures NFL Team Yearbook Ads Across 25 Stadiums
• InvestorNewsBreaks - SEGG Media Corporation (NASDAQ: SEGG, LTRYW) Appoints Former Live Nation Europe President Simon Lewis to Lead Concerts.com, TicketStub.com Rollout

Massimo Group (NASDAQ: MAMO)

The QualityStocks Daily Newsletter would like to spotlight Massimo Group (NASDAQ: MAMO).

Massimo's recent expansion into Oregon and Arkansas adds over 100 big-box retail locations, positioning the company for significant holiday season growth through enhanced market penetration

The company's Vietnam manufacturing partnership delivers supply chain diversification and cost efficiency while maintaining quality control for its feature-rich six-seater golf carts

Strategic global sourcing improvements have reduced lead times and increased operational flexibility, enabling Massimo to scale effectively during peak Q3 and Q4 demand cycles

Models that relied on single-source manufacturing and regional distribution are giving way to strategies that emphasize flexibility, diversification, and rapid market penetration. BRP Inc., for example, has expanded production beyond North America with facilities in Mexico and Finland, enabling it to serve global markets more effectively while reducing reliance on U.S. manufacturing. By diversifying operations across regions, powersports companies are better equipped to manage supply chain risks and maintain a competitive edge. The challenge lies in balancing growth ambitions with operational complexity. Expanding into new markets requires coordination across licensing, retail partnerships, inventory management, and logistics networks. Supply chain disruptions create unpredictable challenges that can derail expansion plans or compromise product availability during critical selling seasons. Successful manufacturers maintain diversified manufacturing capabilities, establish strong retail partnerships, and implement flexible logistics models that adapt to changing conditions. Most importantly, they understand that sustainable growth requires building operational infrastructure that can support expansion rather than simply pursuing geographic reach.That operational sophistication defines Massimo Group (NASDAQ: MAMO) ("Massimo Group" or "Massimo"), a powersports manufacturer demonstrating how strategic expansion combined with supply chain innovation creates meaningful competitive advantages.

Massimo Group (NASDAQ: MAMO) is a prominent manufacturer and distributor specializing in powersports vehicles and recreational watercraft. Established in 2009, the company has built a reputation for delivering value-packed utility terrain vehicles (UTVs), all-terrain vehicles (ATVs), and on-road vehicles to both recreational enthusiasts and professionals in the agricultural sector. In 2020, Massimo expanded its offerings by launching Massimo Marine, dedicated to crafting high-quality watercraft with advanced designs and exceptional customer service.

Massimo Group is focused on sustainability. Its recent initiatives, including the introduction of the MVR Series of electric carts, highlight the company’s commitment to eco-friendly solutions that address growing consumer demand for sustainability in the powersports and marine industries.

The company’s manufacturing capabilities have also evolved significantly. Its expanded 376,000-square-foot facility in Garland, Texas, now features advanced automation, including a vehicle assembly robot line. This addition is expected to significantly enhanced production capacity and efficiency, enabling Massimo to scale its operations and better meet market demand.

Product Portfolio

Massimo Group’s product portfolio showcases its dedication to innovation and versatility. Its diverse lineup combines advanced features, sustainability, and value to meet the needs of a dynamic market.

• Massimo Motor: This category includes a wide range of UTVs, ATVs, go-karts, and mini-bikes designed for both recreational and practical applications. Notable recent additions include the T-Boss 1000 UTV, which combines rugged performance with advanced features, and the GKD 350 All-Terrain Go-Kart, a versatile two-seater ideal for various terrains. The Buck 550-6 Crew, a six-seater UTV, further expands this lineup, providing comfort and utility for families and light-duty users at an accessible price point.
• Massimo Marine: Specializing in pontoon and tritoon boats, this division emphasizes luxury and performance. A recent collaboration between Massimo and Vision Marine Technologies has introduced electric pontoon platforms, catering to consumers seeking eco-friendly watercraft for both commercial and recreational use.
• Massimo Electric: Reflecting the company’s commitment to sustainability, Massimo Electric focuses on low-speed electric vehicles (LSVs) tailored for diverse applications. Recent launches include the MVR 2X Golf Cart and MVR Cargo Max Utility Cart, which deliver advanced features and versatility for recreational users and professionals in industries like farming and groundskeeping.

By combining practicality with cutting-edge design, Massimo Group seeks to set the standard in the powersports and marine industries.

Market Opportunity

The global ATV and UTV market is experiencing robust growth, with North America projected to reach approximately $9.18 billion in 2024 and expand at a compound annual growth rate (CAGR) of 7.8% to $13.37 billion by 2029, according to Mordor Intelligence. Likewise, the U.S. electric UTV and ATV powertrain market is rapidly expanding. It was valued at $2.46 billion in 2022 and is expected to grow at a CAGR of 10.2%, reaching $5.18 billion by 2030, as reported by Grand View Research.

The pontoon boat market complements this growth, driven by increased interest in leisure and marine tourism. The market size exceeded $7.9 billion in 2022 and is projected to grow at a CAGR of 8.3% through 2032, according to Global Market Insights. Massimo Marine’s introduction of electric pontoon platforms through its Vision Marine partnership is expected to position the company to effectively address this growing market segment.

With strategic partnerships and an expanding dealer network, Massimo believes it is poised to penetrate deeper into domestic and international markets. The company’s service coverage currently includes over 2,800 retail locations, 600 motor service centers, and 5,500 marine service centers, ensuring robust support and accessibility for customers. This extensive distribution network underpins Massimo’s ability to capture market share and drive sustained growth.

Leadership Team

David Shan, Founder, Chairman, and CEO, established Massimo Motor in 2009 and Massimo Marine in 2020. He has led the company through significant growth phases, including the development of diverse product lines and its public listing. Shan holds a bachelor’s degree in international trade from Qingdao Ocean University of China.

Dr. Yunhao Chen, CPA, serves as the company’s Chief Financial Officer, bringing extensive experience in capital markets, financial reporting, and corporate governance since her appointment in May 2023. She holds a Ph.D. in Accounting and an MBA in Finance from the University of Minnesota.

Michael Smith, Vice President, joined Massimo in 2019 and played a pivotal role in launching Massimo Marine. With a strong background in powersports retail and product innovation, he is dedicated to driving new product development. Smith studied International Business and Marketing at the University of California, San Diego.

Massimo Group (NASDAQ: MAMO), closed Friday's trading session at $2.96, up 3.8596%, on 84,944 volume. The average volume for the last 3 months is 71,183 and the stock's 52-week low/high is $1.839/$4.6599.

Recent News

• Massimo Group (NASDAQ: MAMO) - Massimo Group Inc. (NASDAQ: MAMO): How Strategic Expansion Is Redefining Distribution
• Massimo Group Announces Launch of New Electric UTV for 2026, Expanding Into Growing EV Market
• PHEVs Provide the Sweet Spot Between Gasoline and Pure Electric Vehicles 

Oncotelic Therapeutics Inc. (OTCQB: OTLC)

The QualityStocks Daily Newsletter would like to spotlight Oncotelic Therapeutics Inc. (OTCQB: OTLC).

CEO Dr. Vuong Trieu recognized as inventor of multibillion-dollar oncology assets, including Abraxane(R) and Cynviloq(TM)

OTLC advancing late-stage pipeline led by OT-101 in Phase 3 for pancreatic cancer and multiple other high-unmet-need indications

Recent progress includes 2 years of steady clinical and regulatory advancements across oncology and rare pediatric programs

Oncotelic Therapeutics (OTCQB: OTLC) is featured in a new NetworkNewsAudio Audio Press Release (APR) titled "Innovative Therapeutics Pipeline Positions Industry for Strong Market Growth." The release highlights the leadership of chair and CEO Dr. Vuong Trieu, who has filed more than 500 patent applications and holds 75 issued patents spanning oncology, immunotherapy and nanomedicine. Dr. Trieu previously developed Abraxane(R), a nanotechnology-based formulation that transformed treatment for breast, lung and pancreatic cancers, and advanced Cynviloq(TM), a novel micellar paclitaxel therapy. The feature underscores how his track record and expertise position Oncotelic to advance pioneering therapies with strong market potential.

To view the full press release, visit https://ibn.fm/2Ir6y

Oncotelic Therapeutics Inc. (OTCQB: OTLC) is a clinical-stage biopharmaceutical company developing RNA-based, immunotherapy, and targeted therapeutics for cancer and other underserved diseases. The company is focused on transforming outcomes for patients with difficult-to-treat and rare conditions, particularly pediatric cancers and aggressive solid tumors. Its development strategy centers on novel compound design, nanoparticle drug delivery, and the integration of artificial intelligence to accelerate discovery and regulatory workflows.

At the center of this foundation is Chairman and CEO Dr. Vuong Trieu, a prolific industry pioneer who has filed more than 500 patents with 75 issued patents across biologics, small molecules, nanoparticles, and diagnostics. Dr. Trieu co-invented Abraxane® (sold to Celgene for $2.9 billion), underscoring his track record of creating high-value therapies. Through collaborations with industry leaders and its stake in specialized joint ventures, Oncotelic is positioned to advance a diverse portfolio of oncology assets with greater speed and cost efficiency. The company also operates a proprietary AI platform, PDAOAI, which streamlines scientific writing, regulatory documentation, and data interpretation. This system is accessible to the public through a dedicated Discord server, offering real-time engagement with Oncotelic’s research ecosystem.

With expanded clinical activity and a next-generation development model, Oncotelic continues to evolve as a multi-asset innovator in precision oncology.

The company is headquartered in Agoura Hills, California.

Pipeline and Partnerships

Oncotelic’s lead candidate is OT-101, currently in a Phase 3 trial for pancreatic ductal adenocarcinoma (STOP-PC study) and evaluated in gliomas and metastatic solid tumors in combination with IL-2 and checkpoint inhibitors. The antisense molecule targets TGF-β2, a cytokine known to suppress immune responses and promote tumor growth. A Phase 1 trial combining OT-101 with IL-2 was recently completed, demonstrating safety and paving the way for combination therapies with PD-1 blockers and other immunotherapies.

Recent data have further strengthened the rationale for OT-101 in pancreatic ductal adenocarcinoma (PDAC). In June and July 2025, two peer-reviewed studies published in the International Journal of Molecular Sciences identified TGF-β2 gene expression and methylation status as significant prognostic markers in PDAC, particularly among younger patients and those with low CD8+ T-cell infiltration. High TGF-β2 expression correlated with reduced overall survival, while elevated TGF-β2 methylation was associated with improved outcomes. These findings validate TGF-β2 as a high-priority target and support the continued development of OT-101 as a precision therapy. Both studies leveraged Oncotelic’s proprietary AI-driven platform, PDAOAI, to mine and assemble multi-omic datasets, showcasing the system’s role in accelerating insight generation.

The company holds a 45% ownership stake in GMP Biotechnology Limited, a joint venture with Dragon Capital Overseas Limited. GMP Bio owns SAPU Bioscience, which is executing several pipeline programs. SAPU and Oncotelic are jointly utilizing a rapid IND platform through their partnership with Shanghai Medicilon to support regulatory filings for up to 20 drug candidates, with five INDs already underway. This collaboration is central to accelerating development of next-generation anticancer agents.

After the joint venture, Dr. Trieu, with his team, built out a state of the art and GMP-certified R&D facility in San Diego, which operates under SAPU, that manufactures clinical trial materials and supports a proprietary nanoparticle platform trademarked Deciparticle ™. This platform includes four therapeutic candidates—two of which are in late-stage manufacturing and expected to enter IND filing before the end of 2025.

Additionally, Oncotelic owns AL-101, an intranasal administered apomorphine product intended for the treatment of Parkinson’s disease, Erectile Dysfunction, and Female Sexual Disorders.

Market Opportunity

Oncotelic is targeting large and underserved therapeutic markets with significant commercial potentials. The global pancreatic cancer treatment market alone is projected to grow at a 12.3% CAGR, reaching $5.84 billion by 2030, up from $2.92 billion in 2024, according to Research and Markets. This growth is driven by increased disease prevalence, aging populations, and demand for more effective treatment options. Notably, the incidence of early-onset PDAC is rising at an estimated rate of 4% per year in the 15–34 age group, highlighting an emerging unmet need for targeted therapies among younger patients.

Beyond oncology, Oncotelic intends to develop AL-101 for Parkinson’s disease, which affects over 1 million patients in the U.S. alone and is expected to impact 1.2 million by 2030. Erectile Dysfunction and Female Sexual Dysfunction are also major global health issues, with Erectile Dysfunction affecting up to 70% of men over 60 and Female Sexual Dysfunction impacting approximately 40% of women—both with limited treatment options, particularly for patients who fail to respond to existing medications. These underserved populations offer fertile ground for innovative new therapies.

Leadership Team

Dr. Vuong Trieu is the Chairman and CEO of Oncotelic Inc. An accomplished innovator in pharmaceutical development, Dr. Trieu previously served as President and CEO of Igdrasol, where he pioneered the approval path for paclitaxel nanomedicine via a single bioequivalence trial. After Igdrasol merged with Sorrento Therapeutics, he became Chief Scientific Officer and a Board Director. He also held leadership roles at Cenomed, Abraxis, Applied Molecular Evolution, and Parker Hughes Institute. Dr. Trieu holds a Ph.D. in Molecular Microbiology, a B.S. in Botany, has published widely, and filed over 500 patent applications with 75 issued U.S. patents.

Amit Shah is the Chief Financial Officer of Oncotelic Inc. He has over 20 years of financial leadership in life sciences, including CFO roles at Marina Biotech and Igdrasol, and senior positions at ISTA Pharmaceuticals, Spectrum Pharmaceuticals, and Caraco. He also worked in consulting and ERP implementation. Mr. Shah holds a Bachelor of Commerce from the University of Mumbai, is an Associate Chartered Accountant in India, and is an inactive CPA in Colorado.

Dr. Anthony E. Maida III is the Chief Clinical Officer – Translational Medicine at Oncotelic Inc. He has over 25 years of experience advancing cancer immunotherapies and held senior roles at Northwest Biotherapeutics, PharmaNet, and Jenner Biotherapies. He has raised over $200 million for biotech firms and negotiated licensing deals with institutions such as Pfizer, Eli Lilly, and Yale. Dr. Maida holds dual B.A. degrees in Biology and History, an MBA, an M.A. in Toxicology, and a Ph.D. in Immunology, and is active in ASCO, AACR, and other scientific societies.

Oncotelic Therapeutics Inc. (OTCQB: OTLC), closed Friday's trading session at $0.07, up 2.9412%, on 490,150 volume. The average volume for the last 3 months is 319,750 and the stock's 52-week low/high is $0.017/$0.075.

Recent News

• Oncotelic Therapeutics Inc. (OTCQB: OTLC) - Oncotelic Therapeutics Inc. (OTLC): Leadership and Innovation Drive Late-Stage Biotech Momentum
• InvestorNewsBreaks - Oncotelic Therapeutics, Inc. (OTCQB: OTLC) Featured in NetworkNewsAudio Release on Innovative Therapeutics Pipeline
• NetworkNewsBreaks - Oncotelic Therapeutics, Inc. (OTCQB: OTLC) Featured in NetworkNewsWire Editorial on Advancing Cancer Research

Ucore Rare Metals Inc. (TSX.V: UCU) (OTCQX: UURAF)

The QualityStocks Daily Newsletter would like to spotlight Ucore Rare Metals Inc. (TSX.V: UCU) (OTCQX: UURAF).

Ucore Rare Metals (TSX.V: UCU) (OTCQX: UURAF) is positioned as the Trump administration is developing a comprehensive strategy to strengthen the nation's critical minerals production and reduce Chinese market control through guaranteed minimum pricing for domestic rare earth producers. The company "stands uniquely positioned to capitalize on this initiative through its revolutionary RapidSX(TM) technology, which addresses critical bottlenecks in rare earth element separation and processing. A recent article discussing this reads, "The company's flagship RapidSX technology represents a breakthrough in rare earth element separation, offering significant advantages over conventional processing methods. The RapidSX technology platform has been demonstrated to process REEs at least three times faster than a similar CSX plant with the same product throughput, resulting in a significantly smaller physical footprint."

To view the full article, visit https://ibn.fm/4jiC7

Ucore Rare Metals Inc. (TSX.V: UCU) (OTCQX: UURAF) s a critical metals technology company developing scalable rare earth element (“REE”) refining infrastructure in North America. Originally founded in 2006 as a mineral exploration company, Ucore has since evolved into a processing technology innovator focused on commercializing its proprietary RapidSX™ platform under a $18.4 million contract from the U.S. Department of Defense, with additional support from Natural Resources Canada. The company’s flagship deployment is the Louisiana Strategic Metals Complex (“SMC”), with additional SMCs planned to follow.

Ucore’s mission is to help reestablish a domestic REE supply chain by offering competitive, modular processing solutions that reduce dependence on China. Supported by government funding, private capital, and engineering partnerships, Ucore aims to meet growing demand for rare earth oxides in electric vehicles, defense systems, and advanced energy technologies.

The company is headquartered in Halifax, Nova Scotia.

Projects & Technology

RapidSX™ Separation Technology

RapidSX™ is Ucore’s proprietary rare earth separation platform, delivering three times faster processing than traditional solvent extraction (SX) methods. Its current demonstration program in Kingston, Ontario, is being conducted under contract with the U.S. Department of Defense to prove commercial readiness for processing both heavy and light REEs. The project is also supported by Natural Resources Canada.

RapidSX™ employs a column-based design that eliminates the need for powered mixer-settlers, enabling a smaller facility footprint, quicker commissioning, and lower CAPEX and OPEX. The platform is adaptable to light and heavy REE feedstocks and is structured for modular scale-up.

The 52-stage RapidSX™ Commercial Demonstration Plant in Kingston, Ontario—operated in partnership with Kingston Process Metallurgy—has logged thousands of runtime hours and is currently processing rare earth feedstock further to the company’s U.S. Department of Defense contract. In January 2025, Ucore secured a $500,000 non-dilutive grant from Ontario’s Critical Minerals Innovation Fund to support the advancement of the Kingston facility and, in the words of Ontario Mines Minister George Pirie, “build a secure supply chain ready to fuel the technologies of tomorrow.”

Strategic Metals Complex – Louisiana

Ucore has selected an 80,800-square-foot brownfield site within the England Airpark in Alexandria, Louisiana, as the location for its first commercial rare earth refining facility. The Louisiana SMC is expected to scale from 2,000 tonnes per annum (TPA) of total rare earth oxides initially to 5,000 TPA, with potential to ultimately reach 7,500 TPA.

The facility benefits from Foreign Trade Zone (FTZ) status, reducing tariff burdens on imported inputs and enhancing logistics efficiency. In addition to these structural advantages, the state of Louisiana has outlined an incentive package valued at $15 million, including a $900,000 infrastructure grant and $360,000 in additional local support. The project is expected to create 100 family-wage jobs and has received strong support from federal and state officials.

To date, Ucore has secured $2.3 million in milestone payments under its $18.4 million OTA award from the U.S. Department of Defense. In early 2024, the company also secured C$2.16 million in private investment from Hondo Private Equity to support its commercialization efforts.

Bokan-Dotson Ridge REE Project – Alaska

Ucore maintains 100% ownership of the Bokan-Dotson Ridge heavy REE project in Southeast Alaska. A Preliminary Economic Assessment was completed in January 2013. The Alaska Industrial Development and Export Authority (AIDEA) has authorized $145 million in bond financing under SB99 (2014) to support future development.

While Bokan remains a long-term asset, Ucore continues to advance it at a measured pace, complementing its near-term focus on commercial rare earth refining and oxide production at the Louisiana SMC.

Market Opportunity

According to Grand View Research, the global rare earth elements market was estimated at $3.95 billion in 2024 and is projected to grow at a compound annual growth rate (CAGR) of 8.6% from 2025 to 2030. The market outlook remains strong, fueled by the growing demand for permanent magnets and catalysts in the automotive sector.

In March 2025, President Trump invoked the Defense Production Act to prioritize domestic critical mineral production, signaling a national mandate to reduce reliance on “hostile foreign powers’ mineral production.” One month later, the Chinese government enacted immediate export restrictions on seven key rare earth elements, including dysprosium and terbium, further intensifying pressure on Western nations to develop secure and independent supply chains. This underscores the strategic value of Ucore’s domestic separation infrastructure.

Leadership Team

Pat Ryan, P.Eng., Chairman and CEO, is the founder of Neocon International, a leading automotive OEM supplier. He brings over 25 years of experience in global supply chain innovation and has led Ucore since 2014 in its strategic pivot toward rare earth processing.

Peter Manuel, Vice President, CFO & Corporate Secretary, has served as Ucore’s financial lead for 14 years. Trained as a Chartered Accountant, with extensive experience across Canada, England, and Ireland, Mr. Manuel has advised public and private entities on strategic planning, treasury, and assurance.

Michael Schrider, MEng, P.E., Vice President & COO, is a multidisciplinary engineer with over 30 years of experience. He founded and operated engineering firms SAi and ABD and has overseen all phases of Ucore’s technical development since 2016.

Geoff Atkins, Vice President of Business Development, has 30 years of mining experience and was instrumental in advancing both Lynas’ Mt. Weld and Vital Metals’ Nechalacho REE operations. He brings deep operational knowledge and leads feedstock strategy at Ucore.

Ucore Rare Metals Inc. (OTCQX: UURAF), closed Friday's trading session at $3.22, up 19.4343%, on 1,695,585 volume. The average volume for the last 3 months is 589,960 and the stock's 52-week low/high is $0.33/$3.55.

Recent News

• Ucore Rare Metals Inc. (TSX.V: UCU) (OTCQX: UURAF) - InvestorNewsBreaks – Ucore Rare Metals Inc.’s (TSX.V: UCU) (OTCQX: UURAF) RapidSX(TM) Targets REE Bottlenecks with Scalable Solution
• DefenseNewsBreaks - Ucore Rare Metals Inc. (TSXV: UCU) (OTCQX: UURAF) and Metallium (ASX: MTM; OTCQX: MTMCF) Form Strategic Collaboration to Advance Rare Earth Refining
• Ucore Rare Metals Inc. (TSX.V: UCU) (OTCQX: UURAF) Powers North American Rare Earth Independence with Decade-Long Greenland Supply Deal

Brera Holdings PLC (NASDAQ: BREA)

The QualityStocks Daily Newsletter would like to spotlight Brera Holdings PLC(NASDAQ: BREA).

Brera Holdings (NASDAQ: BREA) will rebrand as Solmate, a Solana-focused digital asset treasury and crypto infrastructure company, following an oversubscribed $300 million private investment in public equity (PIPE). The financing was led by Pulsar Group with support from the Solana Foundation, ARK Invest and RockawayX. Marco Santori, former Chief Legal Officer of Kraken, will step in as CEO. Solmate plans to channel capital into revenue-generating infrastructure projects in the UAE, beginning with bare metal servers in Abu Dhabi built to optimize Solana validator performance. Backed by prominent blockchain and investment firms, Solmate seeks to drive Solana adoption across institutional markets, DeFi, NFTs and AI, while anchoring its role in the UAE's digital transformation.

To view the full press release, visit https://ccw.fm/IN5cx

Brera Holdings (NASDAQ: BREA) , which is rebranding as Solmate and pivoting to a Solana-based digital asset treasury and crypto infrastructure, surged after Cathie Wood's ARK Invest purchased 6,500,001 shares valued at about $49.72 million on Sept. 18 through ARKK, ARKW and ARKF funds. The move follows Brera's $300 million oversubscribed private placement backed by Pulsar Group, RockawayX and ARK. Meanwhile, ARK sold 47,474 Roku (NASDAQ: ROKU) shares for roughly $4.67 million and trimmed 43,157 Tempus AI (TEM) shares for $3.73 million, while adding positions in Arcturus Therapeutics (NASDAQ: ARCT), ATAI Life Sciences (NASDAQ: ATAI), AeroVironment (NASDAQ: AVAV), Baidu (NASDAQ: BIDU) and Pony.ai (NASDAQ: PONY). BREA stock is up more than 200% year to date.

To view the full press release, visit https://ibn.fm/HWMac

Brera Holdings PLC (NASDAQ: BREA) is an Ireland-based, international holding company focused on expanding its global portfolio of men’s and women’s sports clubs through a multi-club ownership approach. The company capitalizes on opportunities to earn tournament prizes, secure sponsorships, collect transfer fees, provide professional sports consulting services, and enhance the valuation of its clubs.

Brera Holdings builds on the legacy of Brera FC, an international football club (referred to as soccer in the U.S.), that it acquired in July 2022. Established in 2000 and based in Milan, Italy, Brera FC has distinguished itself by cultivating an alternative football legacy. In October 2024, the Internet Marketing Association awarded Brera FC with the Social Impact Through Soccer accolade at its IMPACT 5050 Conference, recognizing the club’s global perspective and positive contributions to society.

The company’s growth strategy focuses on unlocking value from undervalued sports clubs and talent, driving innovation, and generating socially impactful outcomes. Brera Holdings is actively expanding its Global Sports Group, acquiring professional football and other sports clubs in emerging markets such as Africa, Asia, and Europe.

By targeting top-division teams in less mainstream markets, Brera Holdings aims to strengthen its competitive position in regional tournaments, including those organized by the Union of European Football Associations (UEFA). These acquisitions are expected to enhance sponsorship revenues and create new growth opportunities.

Leveraging its expertise in capital raising and revenue generation, Brera Holdings also anticipates growing demand for its consulting services, providing advisory support to sports clubs, associations, investors, and others. Brera Holdings is headquartered in Dublin, Ireland, with additional offices in Milan, Italy.

Sporting Assets

Brera Holdings continues to grow its global sports portfolio with a series of strategic acquisitions and innovations, including the FENIX Trophy Tournament, a pan-European, non-professional football competition. Launched in September 2021 and organized by Brera FC, the tournament has been recognized by UEFA and described by BBC Sport as “the Champions League for amateurs.” In 2023, Brera FC hosted the tournament’s finals at Milan’s iconic San Siro Stadium.

In March 2023, Brera Holdings expanded into Africa by establishing Brera Tchumene FC in Mozambique. Starting in the country’s Second Division League, the team quickly earned promotion to Moçambola, Mozambique’s First Division League, by November 2023.

In April 2023, Brera Holdings further strengthened its European presence by acquiring a 90% stake in Fudbalski Klub Akademija Pandev, a first-division football team in North Macedonia. This acquisition provides access to two major UEFA competitions, solidifying the company’s position in European football.

Brera Holdings’ reach extends beyond football. In July 2023, it acquired majority ownership of UYBA Volley, an Italian Serie A1 women’s professional volleyball team, demonstrating its commitment to diversifying within top-tier sports.

In September 2023, Brera Holdings entered the Mongolian football market by acquiring Bayanzurkh Sporting Ilch FC, a Mongolian National Premier League team. For the 2024 season, the club was rebranded as Brera Ilch FC, further expanding Brera’s global footprint.

In January 2024, Brera Holdings initiated a proactive search for an Italian Serie B football club, aligning with its goal of bringing multi-club ownership opportunities to mass investors through its Nasdaq-listed shares.

In February 2024, the Brera Holdings Advisory Board was established with MLS founder and World Cup director Alan Rothenberg, luxury lifestyle executive Massimo Ferragamo, sports business leaders Paul Tosetti and Marshall Geller, and Italian football icon Giuseppe Rossi.

In June 2024, the North Macedonian women’s football club Tiverija Strumica officially became part of the Brera family with the establishment of a joint-stock company controlled by Brera Holdings called Women’s Football Club Tiverija Brera AD Strumica (“Brera Tiverija”). Brera Tiverija is now a wholly-owned subsidiary of Brera Strumica FC.

In September 2024 Brera announced that it signed an exclusive letter of intent to acquire an Italian Serie B club (the “LOI” and the “Club”). According to a CFA report published in June 2024, this expected strategic transaction, for an estimated purchase price of $21.6 million, would add first-year annual revenue of $10.8 million to Brera, and that revenue would likely increase by 25% each year for the next three years. The company’s capital valuation, projected the report, would also experience significant appreciation during this period.

In October 2024, Brera was recognized with the 2024 Social Impact Through Soccer Award at IMPACT 5050, an annual event honoring leaders and innovators who significantly impact their industries and communities. This is the second time Brera has won the award.

Market Opportunity

A report from IMARC Group, a global management consulting firm, reveals that the international football market generated approximately $3.3 billion in revenue in 2023, with projections to grow to $4.6 billion by 2032, reflecting a compound annual growth rate (CAGR) of 3.6%. Key drivers behind this growth include advancements in digitization, increasing sponsorship and partnership deals between brands and clubs, the rising interest in women’s professional soccer leagues, and the expansion of the e-sports and gaming sector.

In particular, Serie B Italian football clubs seem to present exceptionally attractive investment opportunities. As of September 2024, more than half of these clubs had appreciated between 80-100% in total market value, post-purchase.

As the world’s most-watched and most-played sport, soccer drives significant demand for football-related products and services, contributing to market growth. Broadcasting rights, sponsorships, and endorsement deals are also major revenue sources for clubs and organizations, with an expanding global fanbase generating new opportunities for financial growth, according to the report.

Management Team

With extensive experience in leadership and finance, Daniel McClory currently serves as the Executive Chairman and Director of Brera Holdings, PLC. He co-founded and held the position of Chief Executive Officer at Boustead & Company Limited, and previously served as the Managing Director, Head of Equity Capital Markets, and Head of China at Boustead Securities, LLC. Mr. McClory’s governance experience includes being a Board Director for USA Track & Field and a member of the Eastern Michigan University Champions Advisory Board. Mr. McClory’s expertise encompasses founding and financing equity capital markets, as well as navigating merger and acquisition transactions and initial public offerings. He holds a BS and MS from Eastern Michigan University, where he also received an honorary Doctor of Public Service. In addition to his professional qualifications, he is fluent in both English and Italian.

Pierre Galoppi serves as the CEO, Interim CFO, and director of Brera Holdings. With over 30 years of experience in strategic business and financial services, his career spans a variety of industries, including natural resources, aviation, cybersecurity, telecommunications, tourism, and international marketing. He has worked extensively across Latin America, the Caribbean, Canada, Europe, and the United States. Mr. Galoppi holds dual citizenship in Canada and Italy and is fluent in English, Spanish, Portuguese, Italian, and French. He earned a Bachelor of Commerce degree and an MBA from Concordia University in Montreal.

Maria Xing serves as the Head of Investments and Corporate Development. She is an executive who has specialized in MCO football (soccer) group investments for 777 Partners, where she was involved in sourcing, direct negotiations, due diligence, and closing deals, including acquiring a controlling stake in Brazilian Serie A football club, Vasco da Gama, and investing in Australian Premier League (“A-League”) side, Melbourne Victory FC. She also played a role in other professional sports franchise portfolio management, including topflight professional football clubs in Italy, France, Germany, and Belgium. Her background is in private equity, investment banking, and finance, with prior experience at The Raine Group, Credit Suisse, and EY (Ernst & Young), as well as previous sports industry experience at Liverpool Football Club in international business development. Ms. Xing earned an MBA from the Wharton School of the University of Pennsylvania and a B.S. from the New York University, Stern School of Business.

Brera Holdings PLC (NASDAQ: BREA), closed Friday's trading session at $16.6, off by 33.3333%, on 22,160,603 volume. The average volume for the last 3 months is 1,740,076 and the stock's 52-week low/high is $4.999/$52.95.

Recent News

• Brera Holdings PLC (NASDAQ: BREA) - MissionIRNewsBreaks - Brera Holdings PLC (NASDAQ: BREA) Jumps as ARK Invest Buys $49.7M Stake, Trims Roku and Tempus AI 
• CryptoNewsBreaks - Brera Holdings PLC (NASDAQ: BREA) Rebrands as Solmate After $300 Million PIPE Led by Pulsar Group with Backing from Solana Foundation, ARK Invest, and RockawayX 
• InvestorNewsBreaks - Brera Holdings PLC (NASDAQ: BREA) to Rebrand as Solmate Following $300 Million PIPE Backed by Solana Foundation, ARK Invest, RockawayX, and Pulsar Group

Bollinger Innovations, Inc. (NASDAQ: BINI)

The QualityStocks Daily Newsletter would like to spotlight Bollinger Innovations, Inc. (NASDAQ: BINI).

Great British Energy (GBE) chairman Juergen Maier has a bold prediction: within a decade, the UK will dominate global markets for cutting-edge renewable technologies. Maier's forecast centers on Britain's potential to master emerging innovations like floating offshore wind and export this know-how worldwide. This isn't wishful thinking, according to Maier, but a realistic assessment of Britain's advantages. The country combines extensive maritime experience, world-class engineering talent, and now substantial government investment through GBE's funding pool of over ten billion dollars. These elements position the UK to capture lucrative international markets while meeting domestic energy needs. The GBE Chairman made the prediction right as Ed Miliband, the UK Energy Security and Net Zero Secretary, published a mission for the government-owned investment body, which will receive a whopping $11.3 billion sourced from windfall taxes levied on gas and oil companies. Britain's window for establishing meaningful market share may be narrower than Maier's decade-long forecast suggests. Nevertheless, Maier remains confident about Britain's prospects thanks to unique advantages such as favorable wind resources, supportive regulatory frameworks, and growing political consensus around clean energy priorities. Combined with GBE's public backing and private sector partnerships, these factors could propel Britain toward the leadership position he envisions. As more countries around the world adopt renewable energy, the market for other clean energy products like the EVs sold by Bollinger Innovations, Inc. (NASDAQ: BINI) is likely to also grow as complimentary technologies depend on and bolster one another.

Bollinger Innovations (NASDAQ: BINI) , an electric vehicle manufacturer, announced it has received $1,074,035 in payments for Class 1, 3 and 4 commercial EV sales completed in August 2025. Payments were received from Pritchard Automotive for DB Schenker and from Ziegler Truck Group, both part of previously announced transactions. Leadership emphasized the importance of the Ziegler sale in building momentum alongside recent cost reductions. Bollinger's lineup includes the Mullen One Class 1 delivery van, the Mullen Three Class 3 utility truck, and the Bollinger B4 Class 4 chassis cab, all fully compliant with U.S. safety and emissions standards.

To view the full press release, visit https://ibn.fm/PLsbd

Bollinger Innovations, Inc. (NASDAQ: BINI) is a Southern California-based automotive company building the next generation of commercial electric vehicles (“EVs”) with United States-based manufacturing located in Tunica, Mississippi.

In August 2023, Mullen began commercial vehicle production in Tunica. As of January 2024, both the Mullen ONE, a Class 1 EV cargo van, and Mullen THREE, a Class 3 EV cab chassis truck, are California Air Resource Board (“CARB”) and EPA certified and available for sale in the U.S. The Company’s commercial dealer network consists of Papé Kenworth, Pritchard EV, National Auto Fleet Group, Ziegler Truck Group, Range Truck Group, Eco Auto, and Randy Marion Auto Group, providing sales and service coverage in key West Coast, Midwest, Pacific Northwest, New England, and Mid-Atlantic markets.

In September 2022, Bollinger Motors, of Oak Park, Michigan, became a majority-owned EV truck company of Mullen Automotive. Bollinger Motors has passed numerous milestones including its B4, Class 4 electric truck production launch on Sept. 16, 2024, and the development of a world-class dealer network with over 50 locations across the United States for sales and service support.

Mullen Commercial

Mullen is defining a new era in commercial vehicles with its connected and customized solutions aimed at making businesses more efficient and profitable.

Mullen ONE Class 1 EV Cargo Van

The Mullen ONE class 1 commercial electric vehicle is the first of its kind in the U.S. market. This van was designed to navigate within narrow urban streets and residential roads, all while maximizing payload and cargo space. The Mullen ONE’s height is less than 6.5 feet, meaning your driver can park the vehicle in a residential garage.

Mullen THREE Class 3 Electric Truck

The efficient urban utility low cab forward features a tight turning diameter of 38 feet and excellent visibility for superior maneuverability on narrow city streets. Even in reverse, maneuverability is a breeze with our standard backup camera and 7-inch display screen. This versatile chassis provides a clean top-of-rail for easy upfitting with bodies up to 14 feet long and over 5,300 lbs of payload. In addition, the design of the LCF chassis allows more cargo length within a given overall length.

Mullen Commercial EVs are eligible for several federal and state level EV incentives, which can be combined for maximized savings.

Mullen ONE:

• $7,500 Federal Tax Credit
• $3,500 MOR-EV Incentive (Massachusetts only)
• $7,500 ComEd Business & Public Sector EV Rebate Program (Illinois only)

Mullen THREE:

• $7,500 Federal Tax Credit
• $45,000 California’s Hybrid and Zero-Emission Truck and Bus Voucher Incentive Project (HVIP) (California only)
• $15,000 MOR-EV Incentive (Massachusetts only)
• $30,000 ComEd Business & Public Sector EV Rebate Program (Illinois only)

In the last two years, Mullen has conducted over 100 vehicle demos or pilots across various industries in the U.S. resulting in significant progress, including new sales opportunities and vehicle orders received and or completed:

• Universities: Princeton University, University of Virginia (UVA), University of California, Los Angeles (UCLA)
• Local city governments: Cities of Dublin, Ohio, Raleigh, North Carolina, Los Angeles, California, Seattle, Washington and Orange County, North Carolina
• Small businesses: From local florist shops to health care providers delivering supplies

Mullen has an extensive dealer network in the U.S. with renowned dealers nationwide including:

• Papé Group (California, Oregon, Washington)
• National Auto Fleet Group (California)
• Pritchard EV (Iowa)
• Eco Auto (Massachusetts)
• Ziegler Truck Group (Minnesota)
• Range Truck Group (Washington)
• Mullen Commercial Vehicle Center (California)

Mullen Commercial EVs are available for purchase on Sourcewell under NAFG’s Sourcewell Contract # 091521-NAF which offers Class 1-3 light duty trucks, cars, vans, SUVs, cab chassis, and electric vehicles with related equipment and accessories to U.S. government agencies.

Bollinger Motors

Mullen entered the medium-duty truck classes through its September 2022 acquisition of a controlling interest in EV truck innovator Bollinger Motors. The acquisition gave Mullen access to a significant pipeline of interest from large companies for commercial electric truck classes 3-6 in a wide range of markets, such as last-mile delivery, refrigeration, utilities and upfitters.

The 2025 Bollinger B4 chassis cab is an all-new, all-electric Class 4 commercial truck designed from the ground up with extensive fleet and upfitter input. Bollinger’s unique chassis design protects the 158-kWh battery pack and components to offer unparalleled capability and safety in the commercial market. The vehicle also features a payload in excess of 7,300 pounds with an average driving range of 185 miles. Bollinger Motors began serial production of the B4 on Sept. 16 via its manufacturing partnership with Roush Industries at their facility in Livonia, Michigan.

Bollinger Motors has passed numerous milestones in recent months, including:

• 30 B4s delivered and paid for, worth nearly $4.5 million, since start of production
• Its production launch on Sept. 16 at Roush Industries in Livonia, Michigan
• Achieving FMVSS compliance
• Receiving the Certificate of Conformity from the Environmental Protection Agency, and CARB certification
• The creation of a world-class dealer and service network
• An agreement with Our Next Energy in Novi, Michigan, for battery packs
• Providing a full warranty coverage of the B4 chassis cab
• Announcing Syncron as its warranty administration partner and Amerit Fleet Solutions as its mobile service provider
• A partnership with EO to power EV charging infrastructure, equipment and technology solutions for Bollinger’s dealers and customers

Bollinger Motors has qualified for multiple federal and state incentive programs, including:

• Inflation Reduction Act incentives of up to $40,000 per vehicle
• California: Innovative Small e-Fleet (ISEF) Pilot Program, with incentives up to $120,000 per vehicle
• Massachusetts: voucher of up to $30,000 per vehicle from Massachusetts Offers Rebates for Electric Vehicles (MOR-EV)
• New York: up to $100,000 from NYTVIP through NYSERDA
• Pennsylvania: up to a $20,000 grant from Alternative Fuels Incentive Grant Program (AFIG) of the Pennsylvania Department of Environmental Protection

Mullen FIVE RS

The Mullen FIVE RS is an ultra-high-performance EV Crossover featuring a top speed of over 200 mph and acceleration from 0-60 mph in under 2 seconds. The FIVE RS is equipped with 800-volt architecture, all-wheel drive, two-speed gearbox, and over 1,100 horsepower.

The Mullen FIVE RS is planned for launch in Germany with vehicle sales planned for December 2025. Initial vehicle market territories include the EU in 2025, followed by the UAE and South Africa in early 2026.

Mullen is partnering with Faissner Petermeier Fahrzeugtechnik AG (“FPF”), which has decades of experience in the development and production of serial components and sophisticated vehicles for global brands such as Piech Automotive, Gumpert Automotive and is in partnership with BMW of all the above. FPF is certified according to the IATF standard and fulfills all the special requirements of the Federal Motor Transport Authority in Germany.

EV Market Outlook

The global EV market was reported to consist of 3,269,671 units in 2019, a figure that is expected to grow at a CAGR of 21.1% through 2030 to a total of 26,951,318 units worldwide. This market’s monetary value was estimated at $162.34 billion in 2019 and is expected to grow at a CAGR of 22.6%, resulting in an approximate value of $802.81 billion by 2027. The primary driver for this exponential growth is a worldwide increase in vehicle emissions regulations.

Management Team

Mullen is led by an executive team with extensive EV, OEM and high-growth startup experience.

David Michery is the CEO and Founder of Mullen and has been leading the company and its divisions since inception in 2014. With over 25 years of executive management, marketing, distressed assets, and business restructuring experience, Mr. Michery brings a wealth of relevant knowledge and expertise to the Mullen brand. He has notably created 12 trademarks so far to develop the company brand and vision.

Mr. Michery is working towards a sustainable future by creating a suite of clean-energy, electric vehicles at varied price points. With entirely US based manufacturing and operations, Mr. Michery is also determined to have Mullen Technologies play a role in shaping a self-sustaining local economy by creating more jobs in America.

Mr. Michery manages risks and company expectations as a pathway to success and has personally overseen several businesses that totaled over $1 billion in transactions. His key strength is the ability to be fiscally responsible and lead teams to complete projects on time and within budget. As a seasoned professional in this space, Mr. Michery has demonstrated skill in building businesses from the ground up and into successful entities that subsequently sold for hundreds of millions of dollars.

Bollinger Innovations, Inc. (NASDAQ: BINI), closed Friday's trading session at $0.0491, off by 3.7255%, on 53,180,674 volume. The average volume for the last 3 months is 174,810 and the stock's 52-week low/high is $0.049/$241500000000.

Recent News

• Bollinger Innovations, Inc. (NASDAQ: BINI) - GreenCarNewsBreaks - Bollinger Innovations, Inc. (NASDAQ: BINI) Reports $1.07 Million in August EV Sales
• GBE Boss Foresees the UK Leading in Clean Energy
• German Chancellor Suggests the Country Could Scale Back its Clean Energy Plans

Nutriband Inc. (NASDAQ: NTRB)

The QualityStocks Daily Newsletter would like to spotlight Nutriband Inc. (NASDAQ: NTRB).

Nutriband (NASDAQ: NTRB) is a transdermal pharmaceutical developer that has secured crucial FDA engagement for its lead abuse-deterrent technology. "Nutriband's FDA Type C Meeting approval for AVERSA(TM) Fentanyl signals agency recognition of the product's potential to address critical unmet medical needs. The Sept. 18 meeting with the Division of Anesthesiology, Addiction Medicine, and Pain Medicine focuses on Chemistry, Manufacturing, and Controls (‘CMC') plans spanning the entire development and commercialization timeline," reads a recent article. "This milestone addresses the complete development arc from IND submission through 505(b)(2) NDA approval. The 505(b)(2) pathway allows Nutriband to leverage existing fentanyl safety data while focusing regulatory review on novel abuse-deterrent components."

To view the full article, visit https://ibn.fm/TxVcF

Nutriband Inc. (NASDAQ: NTRB) is engaged in the development of a portfolio of transdermal pharmaceutical products. The company’s AVERSA™ technology can be incorporated into any transdermal patch and includes aversive agents to prevent abuse, diversion, misuse and accidental exposure to drugs with abuse potential, specifically opioids.

AVERSA technology has the potential to improve the safety profile of transdermal drugs susceptible to abuse, such as fentanyl, while making sure that these drugs remain accessible to patients who need them. The technology is covered by a broad intellectual property portfolio with patents granted in the United States, Europe, Japan, Korea, Russia, Canada, Mexico, Australia, and China, with recent extensions into Macao.

The company’s business model is to apply its transdermal technology to existing FDA-approved drugs with a goal of improving safety, efficacy and patient comfort while qualifying for a limited-development regulatory pathway that reduces the number of clinical trials required for approval of new drugs.

Nutriband has three subsidiaries, including 4P Therapeutics, its clinical and regulatory subsidiary; Pocono Pharmaceutical, a contract manufacturer for a wide range of clients; and Active Intelligence, a developer of sports recovery products. This ownership of manufacturing and clinical development capabilities drastically reduces costs for AVERSA and other technologies.

In April 2024, Nutriband announced that the company had been engaged by and received a first order from Fit For Life Group, a major brand license holder. A fully executed supplier agreement is expected to follow. Nutriband’s wholly owned Active Intelligence subsidiary will act as manufacturer.

In February 2025, the company formalized its product development partnership with Kindeva Drug Delivery through a long-term exclusive agreement. The collaboration supports the commercial pathway for AVERSA Fentanyl by leveraging Kindeva’s FDA-approved transdermal fentanyl patch system.

The company is headquartered in Orlando, Florida.

Products

Nutriband’s lead product candidate is AVERSA Fentanyl, an abuse-deterrent fentanyl transdermal patch. The company announced in March 2024 that it will submit a New Drug Application to the U.S. Food and Drug Administration seeking approval to market AVERSA Fentanyl. In subsequent updates, Nutriband confirmed that the NDA submission remains the company’s primary focus and is backed by a strong cash position.

Nutriband has partnered with Kindeva Drug Delivery, a leading global contract development and manufacturing organization, to incorporate Nutriband’s AVERSA abuse-deterrent transdermal technology into Kindeva’s FDA-approved transdermal fentanyl patch system. Because Nutriband’s abuse-deterrent technology is incorporated into the fentanyl patch but is physically separate from and does not come in contact with the drug layer, the clinical trials typically needed to demonstrate safety and efficacy for a new drug formulation would not be required.

In support of this commercialization strategy, Nutriband closed an $8.4 million private placement in April 2024 to fund development activities related to AVERSA Fentanyl. The company also licensed Bitrex®, a widely used aversive agent, to enhance the deterrent profile of its patch formulation.

AVERSA Fentanyl has the potential to be the first and only abuse deterrent patch approved anywhere in the world. The company plans to seek an expedited review by the FDA, as has been granted for certain abuse-deterrent oral opioid products, which shortens the regulatory review period to six months from the conventional 10-month FDA review cycle for NDAs.

Nutriband’s AVERSA product development pipeline also includes abuse deterrent versions of currently approved and marketed transdermal patches containing buprenorphine, an opioid used to treat opioid use disorder, and methylphenidate, a central nervous system stimulant used in the treatment of attention deficit hyperactivity disorder (ADHD). Both are labeled with FDA-required warnings for the risk of abuse and misuse, as well as warnings against accidental exposure.

Market Opportunity

Nutriband cites a market analysis report from Boston-based Health Advances, a healthcare and life sciences consulting firm. According to the report, upon FDA approval, AVERSA Fentanyl has the potential to reach peak annual sales of $200 million in the U.S.

The company further states that, should non-abuse-deterrent transdermal fentanyl products lose FDA marketing approval, AVERSA Fentanyl would have greater pricing flexibility and would have the potential to generate more than $500 million in annual revenue.

Management Team

Gareth Sheridan is Co-Founder and CEO of Nutriband. He was Ireland’s ‘Young Entrepreneur of the Year’ in 2014 for establishing Nutriband. He has worked as a Business Mentor with 100 Minds, a social enterprise that brings together some of Ireland’s top college students and connects them with a cause to achieve large charitable goals. He received a B.Sc. in Business and Management from Dublin Institute of Technology.

Serguei Melnik is Co-Founder and President of Nutriband. He has been involved in general business consulting for companies in the U.S. financial markets and setting up legal and financial frameworks for operations of foreign companies in the U.S. He previously was the COO of Florida-based Asconi Corporation. He also was a lawyer in the Department of Foreign Affairs, JSC Bank “Inteprinzbanca,” in Chisinau, Moldova, and prior to that practiced law in Moldova. He is fluent in four languages.

Jeff Patrick, Pharm.D., is Chief Scientific Officer of Nutriband. He currently serves as Director of the Drug Development Institute at the Ohio State University Comprehensive Cancer Center. His prior roles included Global Vice President at Mallinckrodt Pharmaceuticals Inc.; and roles at Dyax, Myogen/Gilead, Actelion and Sanofi-Synthelabo Inc. He was a clinical pharmacist at the University of Tennessee Medical Center and a clinical assistant professor of pharmacy at the University of Tennessee College of Pharmacy.

Gerald Goodman is CFO of Nutriband. He is a certified public accountant with his own firm, Gerald Goodman CPA. He also practiced with Madsen & Associates, CPAs, and was a partner in the accounting firm of Wiener, Goodman & Company. He is also a director of Lifestyle Medical Network Inc., which provides management services to healthcare providers. He is a graduate of Pennsylvania State University, where he received a bachelor’s degree in accounting.

Nutriband Inc. (NASDAQ: NTRB), closed Friday's trading session at $7.22, off by 0.5509642%, on 36,390 volume. The average volume for the last 3 months is 31,948 and the stock's 52-week low/high is $3.7223/$11.78.

Recent News

• Nutriband Inc. (NASDAQ: NTRB) - MissionIRNewsBreaks - Nutriband Inc. (NASDAQ: NTRB) Eyes Clear Development Pathway for AVERSA(TM) Technology
• Nutriband Inc. (NASDAQ: NTRB): When Market Confidence Validates Scientific Innovation
• BioMedNewsBreaks - Nutriband Inc. (NASDAQ: NTRB) Reports 51% Revenue Growth, Strong Cash Position to Advance AVERSA Fentanyl

Soligenix Inc. (NASDAQ: SNGX)

The QualityStocks Daily Newsletter would like to spotlight Soligenix Inc. (NASDAQ: SNGX).

A grant of $2 million has been awarded to UCLA Health by a for-profit company, ViewRay Systems. The purpose of this grant is to enable the university to accelerate its research efforts in finding ways in which MRI-guided radiation therapy can be leveraged to provide targeted treatment to cancer patients. Cancer treatments, such as radiation and chemotherapy, are known to impact both diseased and healthy tissues. The impact on healthy tissue causes a variety of side effects, such as hair loss and weight loss, which can affect the health and quality of life of patients. Efforts have therefore been made to find ways in which to concentrate as much of the treatment on cancer tissue while limiting the exposure of healthy tissues to radiation and chemotherapy. Secondly, MRIs make it possible to track treatment delivery in real time, which isn't possible with CT scans. With this grant, UCLA plans to conduct trials aimed at showing how best this MRI-guided treatment approach can be used in the treatment of different cancer types since many specialists can work together to directly monitor the radiotherapy as it is being administered and make any needed adjustments while the patient is receiving the treatment, rather than waiting to conduct reviews after a session. This $2m grant is just one example of funding that is going into seeking ways to improve how cancer is treated. Many other companies like Soligenix Inc. (NASDAQ: SNGX) are also directing considerable resources towards developing a new range of treatments to offer better clinical outcomes to patients. 

Soligenix (NASDAQ: SNGX) is a late-stage biopharmaceutical company focused on developing and commercializing products to treat rare diseases with unmet medical need. The company's SGX942 is a novel therapeutic aimed at alleviating oral mucositis, a debilitating side effect of cancer therapy with no FDA-approved treatment. "Severe oral mucositis (‘SOM') often necessitates hospitalization, opioid pain management and feeding tube placement, lowering quality of life substantially. Because of these risks, effective treatment or prevention is critical to ensuring cancer therapies remain on schedule and patients maintain nutrition and comfort," reads a recent article. In response, the company is advancing a promising candidate, SGX942 (dusquetide), which has shown promising outcomes in clinical trials. "Soligenix is in the process of analyzing the combined phase 2 and 3 datasets to design a second pivotal phase 3 study. The company is also in the process of identifying potential partners to continue this development program."

To view the full article, visit https://ibn.fm/fzsyE

Soligenix Inc. (NASDAQ: SNGX) is a late-stage biopharmaceutical company focused on developing and commercializing treatments for rare diseases with high unmet medical needs. Operating through two key segments, the company’s Specialized BioTherapeutics division is dedicated to oncology and inflammation therapies, while its Public Health Solutions segment advances vaccines and therapeutics targeting biothreats and infectious diseases.

The company is actively advancing multiple late-stage clinical programs, including HyBryte™ (SGX301), a novel photodynamic therapy for cutaneous T-cell lymphoma (CTCL). Additional candidates in development target psoriasis (SGX302), oral mucositis (SGX942), and Behçet’s disease (SGX945), while its public health efforts focus on heat-stable vaccines for ricin poisoning (RiVax®), Ebola (SuVax™), and Marburg (MarVax™) viruses, that have been supported by non-dilutive government grants and contracts of approximately $60 million to date.

With a diversified pipeline, multiple orphan and fast-track designations, and collaborations with government agencies, Soligenix is uniquely positioned for potential regulatory approvals and commercialization.

The company is headquartered in Princeton, New Jersey.

Pipeline and Development Programs

Specialized BioTherapeutics

Soligenix’s Specialized BioTherapeutics division develops treatments for oncology and inflammatory diseases, focusing on conditions with few or no effective therapeutic options. HyBryte™ (synthetic hypericin) has completed a Phase 3 study for CTCL, demonstrating statistically significant efficacy, and a second confirmatory Phase 3 trial is actively enrolling patients to support potential regulatory submissions worldwide. If approved, it would be the first non-mutagenic photodynamic therapy for early-stage CTCL, addressing an unmet medical need. It has received orphan drug designations in the U.S. and Europe, as well as Fast Track designation in the U.S.

SGX302, a photodynamic therapy based on the same active ingredient as HyBryte™, is in clinical development for mild-to-moderate psoriasis, with positive Phase 1/2 proof-of-concept results, it is actively enrolling patients in a Phase 2a clinical trial.

SGX942, designed to reduce inflammation and tissue damage in oral mucositis associated with cancer treatment, is progressing as a potential first-in-class therapy.
SGX945, targeting aphthous ulcers in Behçet’s disease, is actively enrolling in a Phase 2a clinical trial and has received fast-track designation, highlighting the urgency of developing effective treatments for this rare inflammatory condition.

Public Health Solutions

The company’s Public Health Solutions segment focuses on medical countermeasures for biothreats and emerging infectious diseases, leveraging non-dilutive government funding to advance its programs. RiVax®, a ricin toxin vaccine, has demonstrated strong preclinical and early clinical results and may be eligible for government procurement under the Strategic National Stockpile initiative.

The company’s RiVax®, as well as its vaccine candidates for Ebola and Marburg viruses are based on its proprietary ThermoVax® technology, which stabilizes vaccines for long-term storage without refrigeration. This approach could be transformative in regions where maintaining cold-chain logistics is challenging.

The ongoing development of these vaccines is supported by funding from NIH, BARDA, and DTRA, with the potential for up to three priority review vouchers (PRVs) upon regulatory approval, to be used for future programs or sold. Notably, PRVs have previously sold for roughly $100 million.

Market Opportunity

Soligenix targets markets with significant commercial potential, focusing on rare diseases and biodefense applications. HyBryte™ addresses CTCL, a disease affecting over 68,000 patients across the U.S. and Europe, with a total market opportunity exceeding $250 million. SGX302, the company’s therapy for mild-to-moderate psoriasis, serves a much larger population, as over eight million people in the U.S. are affected by the condition, representing a global market opportunity exceeding $1 billion.

SGX942, developed for oral mucositis in head and neck cancer patients, is aimed at a market worth more than $500 million, while SGX945 for Behçet’s disease serves a niche segment valued at over $200 million worldwide.

In addition to its rare disease programs, Soligenix’s Public Health Solutions division has the potential to generate significant revenue through government procurement contracts. By focusing on both orphan drug markets and government-funded biodefense initiatives, Soligenix has positioned itself for sustained revenue growth through multiple high-value opportunities.

Leadership Team

Christopher J. Schaber, PhD, Chairman, President & CEO, brings to the company more than 35 years of experience in the biopharmaceutical industry. Before joining Soligenix, he held senior and operational leadership roles at Discovery Laboratories, Acute Therapeutics, Ohmeda Pharmaceuticals, The Liposome Company, and Wyeth Ayerst Laboratories. He has extensive expertise in drug development, regulatory affairs, and corporate strategy, positioning him to drive Soligenix’s growth and advancement toward commercialization.

Richard Straube, MD, Chief Medical Officer, has more than 35 years of experience in drug development and clinical research. Prior to joining Soligenix, he held key leadership roles at Stealth Peptides, INO Therapeutics, Ohmeda Pharmaceuticals, and Centocor. Throughout his career, he has played a crucial role in bringing innovative therapies to market, particularly in inflammatory diseases and immunology, making him a valuable asset in advancing Soligenix’s late-stage clinical programs.

Oreola Donini, PhD, Chief Scientific Officer, has more than 20 years of experience in pharmaceutical research and development, with expertise in immunology, inflammation, and rare diseases. Before joining Soligenix, she held leadership positions at Inimex Pharmaceuticals, ESSA Pharma, and Kinetek Pharmaceuticals, where she worked on novel drug discovery and translational medicine. Her experience in preclinical research and product development supports Soligenix’s continued innovation in biopharmaceuticals.

Jonathan Guarino, CPA, CGMA, Chief Financial Officer, has over 25 years of experience in corporate finance and strategic financial planning. Before joining Soligenix, he held financial leadership positions at Hepion Pharmaceuticals, Covance, BlackRock, and Barnes & Noble. His expertise in financial management, accounting, and capital markets plays a critical role in Soligenix’s financial strategy and operational efficiency.

Soligenix Inc. (NASDAQ: SNGX), closed Friday's trading session at $2.69, off by 2.5362%, on 398,399 volume. The average volume for the last 3 months is 8,109,698 and the stock's 52-week low/high is $1.09/$6.2299.

Recent News

• Soligenix Inc. (NASDAQ: SNGX) - InvestorNewsBreaks - Soligenix Inc. (NASDAQ: SNGX) Leveraging Positive Clinical Data to Shape Pivotal SGX942 Trial 
• UCLA Researchers Receive $2M Grant to Study MRI-Guided Cancer Radiation Therapy
• Senior NIH Officials Allege Retaliation as Motive for Their Ouster

Trilogy Metals Inc. (NYSE American: TMQ) (TSX: TMQ)

The QualityStocks Daily Newsletter would like to spotlight Trilogy Metals Inc. (NYSE American: TMQ) (TSX: TMQ).

H.J. Res. 106 is designed to overturn the Central Yukon Resource Management Plan ("RMP"), a plan that has locked up 13 million acres of public land in Alaska

The Ambler Access Project is a proposed 211-mile, industrial-use-only road that would connect Trilogy Metals' Upper Kobuk Mineral Projects to the Dalton Highway

These key policy moves to reverse land restrictions and advance the Ambler Road permit mark major inflection points for Trilogy Metals

A wave of policy changes at the federal level has delivered two major developments that could unlock value for Trilogy Metals (NYSE American: TMQ) (TSX: TMQ) . First, the U.S. House of Representatives passed a resolution to overturn restrictive land designations in central Yukon, opening up millions of acres previously locked from development ( ibn.fm/3YK2M ). Second, federal executive action has advanced the proposed Ambler Access Road in Northwest Alaska, a long-sought industrial corridor that Trilogy has noted is essential to accessing its mining assets in the Ambler Mining District ( ibn.fm/iF662 ). Together, these moves reduce key regulatory obstacles for Trilogy Metals and sharpen the prospects for its copper-dominant polymetallic projects.

Trilogy Metals (NYSE American: TMQ) (TSX: TMQ) is positioned for opportunity as AI data centers are projected to consume more than 4 million tonnes of copper by 2035, intensifying global demand. "Through Ambler Metals LLC, its 50/50 joint venture with South32, Trilogy controls the Upper Kobuk Mineral Projects in Alaska's Ambler Mining District. The district hosts volcanogenic massive sulphide (‘VMS') and carbonate replacement deposits containing copper, zinc, lead, gold, silver, and cobalt," reads a recent article. "AI-driven data centers, combined with renewable energy and electrification, are reshaping copper's demand profile. With a 50% stake in one of North America's most prospective copper districts, Trilogy Metals is well positioned to benefit. Its high-grade deposits, strong partnerships, and supportive policy environment provide a foundation to meet the challenges of a tightening copper market. As the global shortfall looms, projects like Arctic and Bornite could play a vital role in securing future supply."

To view the full article, visit https://ibn.fm/HnAdr

Trilogy Metals Inc. (NYSE American: TMQ) (TSX: TMQ) is a North American mineral exploration and development company focused on advancing high-grade copper and critical mineral assets in Alaska. The company operates through Ambler Metals LLC, a 50/50 joint venture with South32 Ltd., and is progressing one of the world’s most prospective undeveloped polymetallic districts.

Trilogy is uniquely positioned with exposure to copper, zinc, lead, cobalt, silver, and gold—commodities vital to global electrification and energy transition. Its vision is to responsibly develop the Ambler Mining District into a premier domestic source of critical minerals while delivering long-term value to shareholders and local communities.

The company is guided by values of trust, respect, integrity, and partnership, and works closely with Alaska Native stakeholders to advance its strategy in a sustainable and inclusive manner.

Projects

Arctic Project

The Arctic project is Trilogy’s flagship asset and one of the highest-grade known copper deposits in the world, with an average grade of approximately 5% copper equivalent. Located roughly 470 kilometers northwest of Fairbanks, Alaska, Arctic is a volcanogenic massive sulphide (VMS) deposit hosting copper, zinc, lead, gold, and silver. The project is at the feasibility stage and is currently undergoing permitting activities.

According to the 2023 Feasibility Study, Arctic will support a 10,000 tonne-per-day open-pit mining operation over a 13-year mine life. Based on long-term metal prices of $3.65/lb copper, $1.15/lb zinc, $1.00/lb lead, $1,650/oz gold, and $21.00/oz silver, the project demonstrates a pre-tax NPV8% of $1.5 billion and an IRR of 25.8%. After-tax, the NPV8% is $1.1 billion with a 22.8% IRR. At April 2025 spot metal prices, the after-tax NPV8% increases to $1.9 billion with a 31.1% IRR.

The project’s metallurgy supports high recoveries: 92.1% for copper, 88.5% for zinc, and 61.3% for lead. Life-of-mine payable production is projected to total 1.9 billion pounds of copper, 2.2 billion pounds of zinc, 335 million pounds of lead, 423,000 ounces of gold, and 36 million ounces of silver. Cash costs are expected to average $0.72 per pound of payable copper, with all-in costs estimated at $1.61 per pound.

Bornite Project

Located approximately 25 kilometers southwest of Arctic, the Bornite project is a large-scale carbonate replacement copper deposit with significant upside. According to the 2025 Preliminary Economic Assessment (PEA), Bornite is expected to support a 6,000 tonne-per-day underground operation over a 17-year mine life, using re-purposed infrastructure from the Arctic Project.

Bornite contains an estimated 6.5 billion pounds of inferred copper. The PEA outlines pre-tax NPV8% of $552.1 million and IRR of 23.6%, with an after-tax NPV8% of $393.9 million and IRR of 20.0%, based on a copper price of $4.20/lb. Total payable copper production over the life of mine is projected at 1.9 billion pounds.

Bornite’s mineralization occurs in stacked, stratabound zones rich in chalcopyrite, bornite, and chalcocite. A subset of the South Reef zone offers high-grade underground mining potential, further enhancing Bornite’s future optionality.

Exploration Pipeline

The Upper Kobuk Mineral Projects span 471,796 acres and include more than 30 additional mineralized prospects beyond Arctic and Bornite. These lie along two geologically distinct and highly mineralized belts: the Ambler Schist Belt and the Bornite Carbonate Sequence.

The Ambler Schist Belt features multiple VMS-style prospects along its 100-kilometer strike length, including Sunshine, Snow, Nora, Shungnak, and BT. Neighboring deposits like Smucker (Teck) and Sun (Valhalla Metals) affirm the district’s regional potential. Ten of Trilogy’s VMS prospects have been drill tested with encouraging results.

Meanwhile, the Bornite Carbonate Sequence extends 16 kilometers along the Cosmos Hills and hosts additional targets such as Pardner Hill and Aurora Mountain. These zones show strong signs of copper and cobalt mineralization and were partially tested during the Kennecott era, suggesting significant room for expansion.

Together, these assets form the foundation of a multi-decade development and discovery platform in one of the most prospective undeveloped mining districts in North America.

Market Opportunity

Trilogy Metals is poised to benefit from long-term structural demand for copper and other critical minerals essential to electrification, energy infrastructure, and clean technologies. Copper, in particular, is expected to see major supply shortfalls due to underinvestment and accelerating demand from power grids, EVs, and data centers.

According to a Grand View Research report, the global copper market is projected to grow from $241.88 billion in 2024 to $339.95 billion by 2030, at a CAGR of 6.5%, driven by the energy transition and rising infrastructure investments.

Trilogy’s Arctic and Bornite projects are strategically located in Alaska, a top-tier mining jurisdiction with strong permitting frameworks and growing federal and state-level support, including recent executive orders streamlining approvals for the Ambler Access Project. The company also maintains a $50 million shelf prospectus and an active $25 million ATM equity program to fund future development.

Leadership Team

Tony Giardini, President and Chief Executive Officer, leads Trilogy Metals with extensive executive experience in the mining industry. He previously served as President of Ivanhoe Mines Ltd., and as Executive Vice President and Chief Financial Officer at Kinross Gold Corporation. Earlier in his career, he held senior roles at Placer Dome Inc. and KPMG. Mr. Giardini is both a Chartered Professional Accountant and a Certified Public Accountant.

Elaine M. Sanders, Chief Financial Officer and Corporate Secretary, brings over 25 years of financial and accounting experience to Trilogy. She is responsible for the company’s financial reporting, compliance, and governance functions. Ms. Sanders has overseen multiple financings and exchange listings throughout her career. She holds a Bachelor of Commerce from the University of Alberta and is both a Chartered Professional Accountant and Certified Public Accountant.

Richard Gosse, Vice President, Exploration, is a veteran geologist with 35 years of global exploration experience. He previously led exploration initiatives at Dundee Precious Metals and Ivanhoe Mines Ltd., where he oversaw the discovery efforts at the renowned Oyu Tolgoi copper-gold project in Mongolia. Mr. Gosse holds a B.Sc. in Geology from Queen’s University and an M.Sc. in Mineral Exploration from Imperial College London.

Trilogy Metals Inc. (NYSE American: TMQ), closed Friday's trading session at $2.02, off by 1.4634%, on 439,424 volume. The average volume for the last 3 months is 516,881 and the stock's 52-week low/high is $0.47/$2.19.

Recent News

• Trilogy Metals Inc. (NYSE American: TMQ) (TSX: TMQ) - Trilogy Metals Inc. (NYSE American: TMQ) (TSX: TMQ) Poised to Gain from Alaska Land, Road Policy Shifts
• InvestorNewsBreaks - Trilogy Metals Inc. (NYSE American: TMQ) (TSX: TMQ) Poised as AI and Electrification Reshape Copper Markets
• Trilogy Metals Inc. (NYSE American: TMQ) (TSX: TMQ) at the Crossroads of National Security and Critical Mineral Supply

Micropolis Holding Co. (NYSE American: MCRP)

The QualityStocks Daily Newsletter would like to spotlight Micropolis Holding Co. (NYSE American: MCRP).

Micropolis specializes in UGVs, AI systems, and modular robotics platforms for security, industrial, urban, and other applications, while pursuing a broader strategy to supply its flexible, scalable, autonomous AI robotics solutions across global markets to a variety of sectors.

The recently announced expansion grants AERXIO sole rights to distribute Micropolis's unmanned ground security vehicles across Egypt and North Africa.

The flagship platform "The Patrol," designed for desert and border operations, will be central to the rollout.

Expansion aligns with rising demand for AI-driven security and surveillance technologies in the region, and reflects growing opportunities for flexible AI robotics worldwide.

Micropolis Holding (NYSE American: MCRP) , a pioneer in unmanned ground vehicles ("UGVs") and AI-driven robotics solutions, has announced a major step in its international expansion strategy through an exclusive distribution agreement with AERXIO FZ-LLC. AERXIO, a UAE-based technology provider, will serve as the sole distributor of Micropolis's advanced unmanned ground security vehicles and related technologies across Egypt and North Africa ( https://ibn.fm/BAiX7 ).

Micropolis Holding Co. (NYSE American: MCRP) is a robotics and AI technology company pioneering the development of unmanned ground vehicles (UGVs), autonomous mobility platforms, and smart infrastructure for security, industrial, and urban applications. Since its founding in 2014, the company has evolved from a software startup into a fully integrated robotics manufacturer with expertise spanning mechatronics, embedded systems, AI software, and high-level autonomy. Its core technology is centered on modularity and adaptability, enabling Micropolis to deploy scalable robotics solutions across a wide range of industries and environments.

The company’s mission is rooted in a vision of harmonious human-machine collaboration, where intelligent automation drives sustainable progress. Through a growing portfolio of partnerships with public and private sector clients, including defense agencies, municipalities, and industrial operators, Micropolis aims to transform how the world approaches mobility, surveillance, and operational efficiency. These solutions are engineered not just to automate tasks, but to meaningfully enhance safety, sustainability, and strategic readiness in high-impact environments.

Following its initial public offering on the NYSE American in March 2025, Micropolis has accelerated the rollout of its autonomous platforms through regional pilots, strategic agreements, and ongoing R&D efforts.

The company is headquartered in Dubai, UAE.

Products

Micropolis offers a robust portfolio of autonomous robotics platforms, control systems, and AI software designed to meet the complex needs of security, industrial, and smart city applications.

M-Platform

Micropolis’ core robotics architecture is built around the M-Platform, a modular autonomous system composed of two primary components: a Mobility-Specific Platform (MSP) and an Application-Specific Pod (ASP). The MSP includes drive-by-wire and steer-by-wire systems, a custom suspension framework, and integrated power storage, all designed for durability and maneuverability in both urban and off-road environments. These platforms are compatible with a wide range of ASPs, enabling the same robotic base to be rapidly reconfigured for use cases in law enforcement, logistics, environmental cleanup, or public safety.

Advanced features across the platform include autonomous driving software, centralized control units, and AI-enhanced power management. Supporting technologies such as the Micropolis Robotic Control Unit (MRCU) and Smart Power Distribution Unit (SPDU) ensure high reliability, energy efficiency, and seamless integration with third-party systems. A compact mechanical design, high-precision control, and in-house R&D allow for scalable customization to match industry-specific requirements.

M-Patrol

The M-Patrol series includes specialized autonomous security and policing robots developed in collaboration with Dubai Police and other governmental entities. The M01 Patrol Unit is designed for open-road deployment, with speeds of 40–47 km/h and features like 360-degree AI vision, license plate recognition, crowd monitoring, and autonomous navigation. It is suited for high-traffic environments where rapid mobility and broad coverage are required.

The M02 Patrol Unit is built for enclosed or pedestrian-rich settings such as gated communities, offering a top speed of 7–10 km/h. It delivers low-speed, high-precision surveillance while maintaining safety in public-facing operations. In August 2025, Micropolis launched the final testing phase of the M02 platform in partnership with Dubai Expo City, Transguard Group, and Dubai Police. This pilot focused on validating advanced features including facial recognition, suspect tracking, behavior analysis, and autonomous navigation. Like the M01, the M02 is compatible with Micropolis’ proprietary command systems and can operate autonomously or under remote supervision.

Microspot

Microspot is Micropolis’ proprietary AI surveillance and analytics engine integrated into its robotic platforms. Initially co-developed with Dubai Police, Microspot enables real-time behavior analysis, facial recognition, and license plate detection through edge computing and machine learning algorithms. It is optimized for public safety use cases where rapid threat identification and decentralized processing are critical.

Micropolis’ recent agreement with AERXIO grants exclusive distribution rights of the company’s “Patrol” system, powered by Microspot, across Egypt and North Africa. This variant is engineered for border and desert operations, featuring a top speed of 50 km/h, a 15-hour runtime, and rapid charging capabilities. The integration of Microspot technology into these units allows for scalable deployment in both civilian and defense-oriented surveillance infrastructure.

Market Opportunity

Micropolis is strategically positioned to serve the growing demand for autonomous robotics and AI-powered systems across the Gulf Cooperation Council (GCC) and beyond. The company’s solutions address operational needs in urban security, logistics, defense, infrastructure, and environmental management—sectors that are undergoing rapid digital transformation in the Middle East.

Government initiatives in the UAE and Saudi Arabia have propelled the robotics and AI markets forward through funding, regulation, and institutional support. The UAE’s Strategy for Artificial Intelligence and Saudi Arabia’s Vision 2030 have created long-term national frameworks for automation and smart infrastructure adoption. Micropolis’ collaboration with public-sector partners, such as Dubai Police and SEE Holding’s Sustainable City 2.0, is aligned with these policy objectives and reflects growing national demand for autonomous technology.

Leadership Team

Fareed Aljawhari, Founder, Chief Executive Officer & Director, is a seasoned product designer and digital developer with over two decades of experience in Dubai’s digital transformation landscape. He founded Micropolis in 2014 and has led its evolution into a robotics and AI enterprise. He has cultivated strong relationships with government and private entities across the UAE, helping to position the company at the forefront of the region’s technology ecosystem.

Dzmitry Kastahorau, Chief Financial Officer, is a finance executive with international experience across the luxury retail, fashion, and automotive sectors. He holds a master’s degree in international corporate finance from EADA Business School in Barcelona and has previously held senior finance roles at Chalhoub Group, PUIG Spain, and Motherson Automotive in Germany.

Micropolis Holding Co. (NYSE American: MCRP), closed Friday's trading session at $1.41, off by 6%, on 74,653 volume. The average volume for the last 3 months is 116,464 and the stock's 52-week low/high is $1.3/$5.64.

Recent News

• Micropolis Holding Co. (NYSE American: MCRP) - Micropolis Holding Co. (NYSE American: MCRP) Expands into Egypt and North Africa Through Exclusive Distribution Agreement with AERXIO
• TechMediaBreaks - Micropolis Holding Co. (NYSE American: MCRP) Showcases Robotic Forestry Unit at ADNOC Safety Day
• Micropolis Holding Co. (NYSE American: MCRP) Is 'One to Watch'

Izotropic Corp. (CSE: IZO) (OTCQB: IZOZF)

The QualityStocks Daily Newsletter would like to spotlight Izotropic Corp. (CSE: IZO) (OTCQB: IZOZF).

Izotropic (CSE: IZO) (OTCQB: IZOZF) (FSE: 1R3) , a medical device company developing imaging-based products for more accurate breast cancer screening, diagnosis and treatment, announced it has closed a non-brokered private placement of 1.5 million units at $0.25 per unit for gross proceeds of $375,000. Each unit includes one common share and one transferable warrant exercisable at $0.50 for three years. Proceeds will be used for general working capital. An insider acquired 100,000 units under exemptions from MI 61-101 requirements, and the company paid $3,500 and issued 14,000 broker warrants exercisable at $0.25 for three years in connection with the offering.

To view the full press release, visit https://ibn.fm/qjvt4

Izotropic Corp. (CSE: IZO) (OTCQB: IZOZF) is a medical device company advancing dedicated imaging solutions to improve the screening, diagnosis, and treatment of breast cancer. Focused exclusively on this clinical area, Izotropic is developing purpose-built technologies designed to address persistent limitations in conventional breast imaging. Through innovation in both device architecture and image acquisition, the company aims to enhance diagnostic confidence while improving patient experience.

Izotropic’s mission is to deliver transformative tools that empower radiologists, reduce missed cancers, and streamline clinical workflows. By introducing a next-generation imaging platform for breast cancer screening and diagnosis, the company is targeting a clear unmet need in a multibillion-dollar global market. Its vision centers on redefining how breast imaging is performed—shifting away from adaptations of whole-body scanners or 2D mammography toward a fully dedicated approach optimized for breast anatomy.

The company’s strategy is built around a singular platform with expansion potential. Izotropic is focused on commercializing its lead product through a staged pathway that includes regulatory authorization, clinical validation, and strategic investor engagement. In parallel, the company is developing educational tools and communications platforms to raise awareness among patients, clinicians, and stakeholders about the evolving role of dedicated breast imaging technologies in cancer care.

The company is headquartered in Vancouver, British Columbia, with operations in Sacramento, California.

Technology Portfolio

Izotropic’s flagship product is the IzoView Breast CT Imaging System, a dedicated breast imaging platform offering high-resolution, true 3D visualization without compression. The IzoView system was advanced from academic innovation to commercial readiness by Izotropic’s in-house team, building on exclusively licensed technology developed at the University of California, Davis to optimize diagnostic accuracy, patient comfort, and clinical workflow. IzoView integrates proprietary mechanical design, patented hardware innovations, and trade-secret software algorithms, along with AI-driven enhancements designed to improve radiologist performance.

Now in clinical-ready form and housed at Izotropic’s engineering facility in Sacramento, California, IzoView was built under an ISO 13485-compliant quality management system. It is scheduled for use in the company’s planned U.S. clinical trial for FDA market authorization. The device is also central to the company’s broader commercialization strategy, which includes platform extensions and future imaging-based product lines outlined in its recently completed 150-page business plan and financial model.

In preparation for launch, Izotropic is also rolling out strategic awareness platforms. These include a company-hosted podcast and the development of breastct.com, a new educational resource to support patients, clinicians, and stakeholders. These initiatives are designed to enhance engagement, reinforce brand positioning, and build early market traction for IzoView.

Market Opportunity

Izotropic is targeting the global breast imaging market, which is undergoing rapid innovation as healthcare providers seek more accurate, patient-friendly alternatives to traditional mammography. Current screening technologies have well-documented limitations in detecting tumors in women with dense breast tissue, a challenge IzoView directly addresses.

According to a report by MarketsandMarkets, the breast imaging market is projected to grow from $4.3 billion in 2023 to $6.6 billion by 2028, at a compound annual growth rate (CAGR) of 8.9%. Key drivers include the increasing prevalence of breast cancer, the shift toward early detection, and advances in imaging technology such as AI integration and contrast-enhanced diagnostics.

Izotropic’s licensing structure with UC Davis allows the company to pursue either FDA or CE Mark approval, offering flexibility for U.S. and international market entry. Izotropic’s go-to-market plan is supported by ongoing education efforts and a structured clinical strategy, both aligned to accelerate adoption and unlock value in a growing global market.

Leadership Team

Robert Thast, Interim CEO, is the founding executive of Izotropic and has over 30 years of experience leading public companies. He has raised over $100 million in capital, built cross-functional leadership teams, and guided early-stage ventures through public listings and strategic transitions. At Izotropic, he oversees corporate development, financing, and market strategy.

Dr. John Boone, Ph.D., Principal Founder and Director, is a Distinguished Professor of Radiology and Biomedical Engineering at UC Davis. He is a pioneer in breast CT development, having built and tested four dedicated scanners and led trials with nearly 500 women. He has held top roles in AAPM and RSNA and currently serves as Editor-in-Chief of Medical Physics.

Ralph Proceviat, CPA, CFO and Director, brings more than four decades of experience in finance, restructuring, and cross-border operations. He has served as CEO, President, and CFO across multiple sectors and has raised significant capital for both public and private ventures. He is also the founder of C-Suite-Consulting.

Dr. Younes Achkire, Ph.D., Chief Operating Officer and Lead Engineer, is the technical lead behind IzoView. He previously co-founded Zap Surgical Systems and has commercialized FDA-cleared technologies in medtech and clean energy. At Izotropic, he manages engineering, manufacturing, clinical deployment, and operational scale-up.

Izotropic Corp. (OTCQB: IZOZF), closed Friday's trading session at $0.292, off by 9.4854%, on 257,475 volume. The average volume for the last 3 months is 74,680 and the stock's 52-week low/high is $0.0186/$0.3316.

Recent News

• Izotropic Corp. (CSE: IZO) (OTCQB: IZOZF) - BioMedNewsBreaks - Izotropic Corporation (CSE: IZO) (OTCQB: IZOZF) (FSE: 1R3) Launches FAQ Page to Enhance Transparency and Investor Engagement
• Izotropic Corporation (CSE: IZO) (OTCQB: IZOZF): When 15 Years of Data Creates Unassailable AI Advantage
• Izotropic Corporation (CSE: IZO) (OTCQB: IZOZF): Exclusive CADx Patent Positions IzoView as First-Mover in AI-Enhanced Breast CT

D-Wave Quantum Inc. (NYSE: QBTS)

The QualityStocks Daily Newsletter would like to spotlight D-Wave Quantum Inc. (NYSE: QBTS).

D-Wave Quantum Inc. (NYSE: QBTS) is a leader in quantum computing systems, software and services focused on delivering customer value via practical quantum applications for problems such as logistics, artificial intelligence, materials sciences, drug discovery, scheduling, fault detection and financial modeling. As the only provider building both annealing and gate-model quantum computers, the company is unlocking commercial use cases in optimization today, while building the technologies that will enable new solutions tomorrow.

D-Wave is a pioneer in quantum computing, with a history of delivering the world’s first commercial quantum computer; the first real-time quantum cloud service; countless hardware and software product and research milestones; and the planned first cross-platform quantum solution which will deliver both annealing and gate-model quantum computers to customers via an integrated platform. Its current commercial product offerings include: Advantage™ (fifth generation quantum computer), Leap™ (quantum cloud service), Launch™ (quantum computing onboarding service) and Ocean™ (full suite of open-source programming tools).

D-Wave’s relentless pursuit of practical quantum computing has resulted in the technology being used today by some of the world’s most advanced enterprises – more than 25 of the Forbes Global 2000 use D-Wave.

D-Wave’s commercial customers include blue-chip industry leaders like Volkswagen, Accenture, BBVA, NEC Corporation, Save-On-Foods, DENSO and Lockheed Martin. The company boasts an extensive IP portfolio featuring more than 200 issued U.S. patents and over 100 peer-reviewed papers published in leading scientific journals.

Founded in 1999, D-Wave is the world’s first commercial supplier of quantum computers. With headquarters and the Quantum Engineering Center of Excellence based near Vancouver, Canada, D-Wave’s U.S. operations are based in Palo Alto, California.

Advantage™ Quantum Computer

 

With the Advantage™ Quantum Computer, D-Wave has incorporated two decades of experience and over 10 years of customer feedback to create the first and only quantum computer designed for business. The platform features a new processor architecture with over 5,000 qubits and 15-way qubit connectivity. This is 2.5x more connections and more than double the number of qubits than the company’s previous generation quantum computer.

D-Wave’s quantum computers, first located in its facilities in British Columbia, have been available to North American users through its Leap™ quantum cloud service since 2018. It has since introduced new Advantage systems in Julich, Germany, and most recently, Marina Del Rey, California, which marked the availability of the first Advantage quantum computer physically located in the United States.

That new deployment is part of the USC-Lockheed Martin Quantum Computing Center (QCC) hosted at USC’s Information Sciences Institute (ISI), a unit of the University of Southern California’s prestigious Viterbi School of Engineering. Additionally, Amazon Web Services (AWS) and D-Wave announced that the U.S.-based system is available for use in Amazon 2racket, expanding the number to three different D-Wave quantum systems available to AWS users.

Leap Quantum Cloud Service

 

D-Wave’s customers interface with its systems through the Leap™ quantum cloud service. Leap delivers immediate, real-time access to the company’s Advantage quantum computer and quantum hybrid solver service, all with enterprise-class performance and scalability.

Leap allows developers proficient in Python to get started building and running quantum applications. Through a seamless and secure cloud-based connection, users can easily start solving complex problems of up to 1 million variables and 100,000 constraints.

Using Leap, D-Wave customers have developed quantum hybrid applications for use cases in manufacturing, logistics, financial services, life sciences, materials science, retail and transportation. By eliminating the need to wait hours, days or weeks to get good answers to a broad array of problems, D-Wave is helping businesses move forward.

D-Wave Launch

D-Wave Launch™ is the company’s onboarding platform aimed at helping businesses easily start their quantum journey. Through this program, D-Wave’s team of experts and partners aid enterprises in identifying best use cases for quantum and work with them to develop a proof of concept and production pilot.

From there, the team coordinates with customers to get their hybrid quantum applications up and running, providing ongoing Leap quantum cloud access to ensure the application is operating smoothly and delivering real business value.

Target Verticals

While the potential applications for quantum computing are effectively limitless, D-Wave has identified a number of industry verticals as key areas of focus for its quantum architecture, providing case studies for each. These include:

• Manufacturing – D-Wave worked with Volkswagen to identify a commercial optimization application, the binary paint shop problem, which was run on D-Wave’s hybrid solver service. The solver outperformed four purely classical methods on problem sizes at commercial scale (N=3,000). In a separate project, similar inputs were tested using a leading ion trap system, which failed to find any commercial solution.
• Life Sciences – Menten AI makes use of D-Wave quantum computing to assist in the design of novel therapeutic peptides—short strings of amino acids that can act as potent drugs. With the rise of COVID-19, D-Wave’s Advantage system made it possible to identify molecules that might be especially well-suited for binding and inhibiting the related spike protein, producing several promising peptide designs.
• Finance – Multiverse Computing, a leader in developing quantum solutions for the financial sector, leveraged D-Wave’s hybrid solver service in a collaboration with BBVA, one of the world’s largest financial institutions. Multiverse demonstrated management strategies that far exceeded the granularity of traditional returns in a fraction of the time, helping BBVA identify a low-risk portfolio for investment.

Market Opportunity

The quantum computing total addressable market is projected to grow between $450 billion and $850 billion over the next 15 to 30 years, with between $5 billion and $10 billion of anticipated TAM growth coming in the next three to five years, according to Boston Consulting Group. Driving factors behind this growth include rising investments in quantum computing tech by governments and an increasing number of commercial use-cases.

Forward-thinking organizations see quantum as an opportunity to move ahead of the competition. From finding efficiencies and reducing waste to decreasing time to solution and solving problems abandoned due to complexity, the business value is real. According to data from 451 Research, 40% of large enterprises are already experimenting with quantum computing.

D-Wave is strategically positioned – in an industry with significant barriers to entry – as evident by a decades-long track record serving a roster of blue-chip customers. The company is singularly focused on helping its customers achieve clear value by leveraging quantum computing in practical business applications. With a full stack of systems, software, developer tools and services, D-Wave is working to enable enterprises, governments, developers and researchers to access the power of quantum computing, thereby providing an intriguing opportunity for prospective investors.

D-Wave’s current investor base includes PSP Investments, Goldman Sachs, BDC Capital, NEC Corporation, Aegis Group Partners and In-Q-Tel.

Leadership Team

Dr. Alan Baratz has served as the CEO of D-Wave since 2020. Previously, as Executive Vice President of R&D and Chief Product Officer, he drove the development, delivery, and support of all of D-Wave’s products, technologies, and applications. Dr. Baratz has over 25 years of experience in product development and bringing new products to market at leading technology companies and software startups. As the first president of JavaSoft at Sun Microsystems, he oversaw the growth and adoption of the Java platform from its infancy to a robust platform supporting mission-critical applications in nearly 80 percent of Fortune 1000 companies. He has also held executive positions at Symphony, Avaya, Cisco, and IBM. Dr. Baratz holds a doctorate in computer science from the Massachusetts Institute of Technology.

John Markovich is the company’s CFO. He brings to D-Wave over three decades of experience working with rapidly growing private and public technology companies across all stages of development. Mr. Markovich has directed the finance, accounting, tax, treasury, M&A, legal, operations, customer service, IR, HR, and IT functions for companies ranging from privately held pre-revenue startups to an NYSE-listed Fortune 500 multi-national company with over $1.2 billion in annual revenue. During his career, he has negotiated and closed over 150 debt, equity, M&A, and joint venture transactions exceeding $2.5 billion in value; over a dozen private placements; nearly a dozen M&A transactions; and several international joint ventures. Mr. Markovich holds a BS in Business from Miami University and an MBA from the Michigan State Graduate School of Business.

D-Wave Quantum Inc. (NYSE: QBTS), closed Friday's trading session at $26.88, up 11.9067%, on 102,188,600 volume. The average volume for the last 3 months is 40,950,923 and the stock's 52-week low/high is $0.8724/$27.329.

Recent News

• D-Wave Quantum Inc. (NYSE: QBTS) - Albania PM Unveils AI Minister to Stamp Out Corruption
• D-Wave Quantum Inc. (NYSE: QBTS) Announces First-Ever Qubits Japan 2025 Quantum Computing User Conference
• Could AI Soon Replace Teachers in Schools?